Combined Association of Cardiorespiratory Fitness and Body Fatness With Cardiometabolic Risk Factors in Older Norwegian Adults: The Generation 100 Study 

Slides:



Advertisements
Similar presentations
Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.
Advertisements

Factors associated with prediabetes in adult children of patients with premature coronary heart disease; the study of families of patients with premature.
NHANES III Prevalence of Hypertension* According to BMI
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
Date of download: 5/31/2016 From: Metabolic Risk Factors Worsen Continuously across the Spectrum of Nondiabetic Glucose Tolerance: The Framingham Offspring.
Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist Jeffrey J. Pasternak, MD, Eric E. Williamson,
My Treatment Approach to Hairy Cell Leukemia Rahul R. Naik, MD, Alan Saven, MD Mayo Clinic Proceedings Volume 87, Issue 1, Pages (January 2012) DOI:
Volume 32, Issue 9, Pages (September 2016)
Copyright © 2009 American Medical Association. All rights reserved.
Promoting Health and Wellness in the Workplace: A Unique Opportunity to Establish Primary and Extended Secondary Cardiovascular Risk Reduction Programs 
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity  Bjarne M. Nes, PhD, Christian R.
Association of Resistance Exercise With the Incidence of Hypercholesterolemia in Men  Esmée A. Bakker, MSc, Duck-chul Lee, PhD, Xuemei Sui, MD, MPH, PhD,
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Longitudinal Patterns of Cardiorespiratory Fitness Predict the Development of Hypertension Among Men and Women  Xuemei Sui, MD, MPH, PhD, Mark A. Sarzynski,
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know  Siddharth Singh, MD, Kymberly D. Watt,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
“Sick Fat,” Metabolic Disease, and Atherosclerosis
The Inadmissibility of What We Eat in America and NHANES Dietary Data in Nutrition and Obesity Research and the Scientific Formulation of National Dietary.
Jean L. Chan, MD, Martin J. Abrahamson, MD  Mayo Clinic Proceedings 
Dose-Response Relationship Between Severe Hypercholesterolemia and Body Mass Index in Healthy Young Adults  Tomohide Yamada, MD, PhD, Shintaro Yanagimoto,
William L. Lanier, MD  Mayo Clinic Proceedings 
Jane J. Lee, PhD, Alison Pedley, PhD, Kate E
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Reflections on Physical Activity and Health: What Should We Recommend?
Dose-Response Relationship Between Severe Hypercholesterolemia and Body Mass Index in Healthy Young Adults  Tomohide Yamada, MD, PhD, Shintaro Yanagimoto,
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
Fructose as a Driver of Diabetes: An Incomplete View of the Evidence
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:
Promoting Health and Wellness in the Workplace: A Unique Opportunity to Establish Primary and Extended Secondary Cardiovascular Risk Reduction Programs 
Standing, Obesity, and Metabolic Syndrome
Gerry H. Tan, M.D., Roger L. Nelson, M.D.  Mayo Clinic Proceedings 
Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the “Obesity Paradox”  Carl J. Lavie, MD, Richard V.
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity  Bjarne M. Nes, PhD, Christian R.
Longitudinal Patterns of Cardiorespiratory Fitness Predict the Development of Hypertension Among Men and Women  Xuemei Sui, MD, MPH, PhD, Mark A. Sarzynski,
Nonexercise Estimated Cardiorespiratory Fitness and Mortality Due to All Causes and Cardiovascular Disease  Yanan Zhang, MSPH, Jiajia Zhang, PhD, Jie.
Hye-Ryoung Kim, PhD, Hee-Seung Kim, PhD  Asian Nursing Research 
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
Barbara P. Yawn, MD, MSc, MSPH, MeiLan K. Han, MD, MS 
Physical Activity Promotion in the Health Care System
Lipid Profiles in Out-of-Hospital Sudden Unexpected Death
Rajiv Chhabra, MD, James H
Magali P. Disdier Moulder, PharmD, PhD, Jenna M
Maximal Estimated Cardiorespiratory Fitness, Cardiometabolic Risk Factors, and Metabolic Syndrome in the Aerobics Center Longitudinal Study  Conrad P.
Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention  Abdallah Al-Salameh, MD, Philippe Chanson,
Volume 371, Issue 9628, Pages (June 2008)
Sophie K. Kieffer, Nina Zisko, PhD, Jeff S
Scott I. Kahan, MD, MPH  Mayo Clinic Proceedings 
Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients  Ariel Israel, MD, PhD, Ehud Grossman, MD  The.
Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome  Macarena Alpañés, M.D., Manuel.
Rhanderson Cardoso, MD, Roger S
Methylphenidate: Its Pharmacology and Uses
RECORD Study: Enrollment and Outcomes
Medical Treatment of Overactive Bladder: In Response
Ross Arena, PhD, PT, FAHA, Carl J. Lavie, MD  Mayo Clinic Proceedings 
Serum Alkalinization and Hydrogen-Rich Water in Healthy Men
Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease  Dean G. Karalis, MD  Mayo Clinic Proceedings 
Is There an “Asymptote of Gain” Beyond Which Further Increases in Cardiorespiratory Fitness Convey No Additional Benefits on Mortality and Atrial Fibrillation? 
Francesco Zaccardi, MD, PhD, Melanie J
Autonomic Tone and Benefits of Cardiac Rehabilitation Programs
III. Treating dyslipidemias
Prevalence of cardiovascular risk factors compared with the Canadian population. Prevalence of cardiovascular risk factors compared with the Canadian population.
Cindy A. Kermott, MD, MPH, Darrell R. Schroeder, MS, Stephen L
Diagnosis and Management of Headache in Older Adults
Acute and Chronic Seizures in Patients Older Than 60 Years
Predictive Validity of a Medical-Related Cardiorespiratory Fitness Algorithm in Predicting Cardiovascular Disease– and All-Cause Mortality: Implications.
Presentation transcript:

Combined Association of Cardiorespiratory Fitness and Body Fatness With Cardiometabolic Risk Factors in Older Norwegian Adults: The Generation 100 Study  Silvana B. Sandbakk, MSc, Javaid Nauman, PhD, Carl J. Lavie, MD, Ulrik Wisløff, PhD, Dorthe Stensvold, PhD  Mayo Clinic Proceedings: Innovations, Quality & Outcomes   Volume 1, Issue 1, Pages 67-77 (July 2017) DOI: 10.1016/j.mayocpiqo.2017.05.001 Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure Receiver operating characteristic curves for cardiorespiratory fitness (brown line), body mass index (yellow line), waist circumference (brown dashed line), and percent body fat (blue line) for the prediction of high cardiometabolic risk in 505 women and 417 men aged 70 to 77 years. High cardiometabolic risk was defined as the presence of at least 2 of the following 4 risk factors: elevated triglyceride level (≥1.7 mmol/L) or pharmacological treatment of dyslipidemia; reduced high-density lipoprotein cholesterol level (<1.3 mmol/L in women and <1.0 mmol/L in men) or pharmacological treatment of dyslipidemia; elevated blood pressure (systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg) or pharmacological treatment of hypertension; and elevated fasting glucose level (≥100 mg/dL [to convert to mmol/L, multiply by 0.0555]) or pharmacological treatment of diabetes. Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, 67-77DOI: (10.1016/j.mayocpiqo.2017.05.001) Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions